Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.61 |
| ▸ | GAA | P10253 | 10/20 | 0.61 |
| ▸ | HPGD | P15428 | 8/20 | 0.61 |
| ▸ | GLA | P06280 | 6/20 | 0.61 |
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478278 | 0.89 | ALDH1A1 (0.66) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL13481991 | 0.89 | MAPT (0.66) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL6650226 | 0.88 | MAPT (0.64) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL670503 | 0.85 | MAPT (0.61) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL8329505 | 0.85 | MAPT (0.57) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL6561148 | 0.82 | MAPT (0.47) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL6561151 | 0.82 | MAPT (0.47) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL1146916 | 0.81 | MAPT (1.00) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL2812534 | 0.81 | RXRA (0.52) | MAPTALDH1A1KDM4EGAAHPGD | |
| SCHEMBL31513297 | 0.81 | KDM4E (0.45) | MAPTALDH1A1KDM4EGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1759095-A | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARM INC (US) | 2006-04-12 | — | — | CN | claimed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100028278-A1 | USE OF CHROMAN-4-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028278-A1 | USE OF CHROMAN-4-ONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008113450-A2 | USE OF CHROMAN-4-ON-DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-0807629-B1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | AVENTIS PHARMA GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6191164-B1 | POTASSIUM CHANNEL MODULATORS; ANTIULCER AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| WO-2000003681-A2 | PROCESS FOR THE SYNTHESIS OF BENZOPYRAN DERIVATIVES | AXYS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | disclosed |
| EP-0807629-A1 | Sulfonamido substituted chromane derivatives, method for their preparation, their use as medicaments or diagnostic agents aswell as medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | MAPT 675/4885ALDH1A1 527/4885KDM4E 4309/4885 |
| US-20100028278-A1 | USE OF CHROMAN-4-ONE DERIVATIVES | COXFA4L2, TYR, XPA | MAPT 2529/4885ALDH1A1 270/4885KDM4E 547/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | MAPT 159/4885ALDH1A1 2133/4885KDM4E 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.